<DOC>
	<DOC>NCT00328770</DOC>
	<brief_summary>This study investigates whether sirolimus could decrease the rate of hepatoma recurrence after liver transplantation in high risk hepatoma patients.</brief_summary>
	<brief_title>De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma</brief_title>
	<detailed_description>A total of 70 patients with HCC (mean age: 54.6 years, female/male: 12/58) received a liver transplant and were included in the study. Immunosuppression included de novo sirolimus, low-dose calcineurin inhibitor for 6 to 12 months, with short-course (3 months) or no steroids.</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Adult patients with hepatocellular (HCC) carcinoma receiving liver transplant Exclusion criteria: Patients less than 18 years of age</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>liver transplant</keyword>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>sirolimus</keyword>
</DOC>